At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
In Brief
A clinical study evaluating Doppler Ultrasound, SIEMENS S3000 and Verasonics Vantage 256, and 2 other interventions for Kidney Cancer and 2 related conditions. Completed, enrolled 22 participants across 1 site.
Detailed Summary
To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Study Details
Timeline
Interventions
Power Doppler measurements will be made
Vantage 256 used for power Doppler ultrasound, manufactured by Verasonics
Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI).
Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI